CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.

CAR T cells
CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial
CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial
Ashley Yeager | Feb 6, 2020
In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.
Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study
Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study
Kerry Grens | Jan 20, 2020
The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.
A Bright Scientific Future
A Bright Scientific Future
Bob Grant | Jan 13, 2020
We may not have personal jetpacks yet, but the past decade has been marked by life-science revolutions, and the coming years have even more biological breakthroughs in store.
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
Emma Yasinski | Sep 11, 2019
Scientists show the approach can kill cells that cause hardening of heart tissue in mice.
Immune Cell Bank Bets on Future CAR T Success
Immune Cell Bank Bets on Future CAR T Success
Nicoletta Lanese | Aug 16, 2019
The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Kerry Grens | Jul 30, 2019
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
T Cell Proliferation Linked to CAR T Responses
T Cell Proliferation Linked to CAR T Responses
Ashley Yeager | Jul 15, 2019
Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.
A Revised CAR T for Lymphoma Has Fewer Side Effects
A Revised CAR T for Lymphoma Has Fewer Side Effects
Kerry Grens | Apr 23, 2019
An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
Kerry Grens | Mar 31, 2019
The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.